866-997-4948(US-Canada Toll Free)

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 107 Pages

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Lymphoma, Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Bacterial Infections, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Leukemias, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Oropharyngeal Cancer, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma Inc
Eli Lilly and Company
FLX Bio Inc
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Teijin Pharma Ltd
Tiziana Life Sciences Plc
ViroStatics srl
XuanZhu Pharma Co Ltd
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1748 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T100182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T100183 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T101551 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
May 17, 2017: Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib at ASCO 2017
May 04, 2017: Breast Cancer Drug Palbociclib could be Temporarily Available to NHS Patients for Free
Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
Apr 24, 2017: Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Demonstrated Superior Progression-Free Survival At Interim Analysis
Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumors
Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting
Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
Mar 31, 2017: IBRANCE (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer
Mar 20, 2017: Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
Mar 17, 2017: KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, Available for Order At Biologics
Mar 13, 2017: Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval
Mar 13, 2017: Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Feb 03, 2017: Breast cancer drug costs too high in relation to benefits for routine NHS funding
Jan 10, 2017: G1 Therapeutics Initiates Phase 2 trial of Trilaciclib in Triple-Negative Breast Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Beta Pharma Inc, H1 2017
Pipeline by Eli Lilly and Company, H1 2017
Pipeline by FLX Bio Inc, H1 2017
Pipeline by G1 Therapeutics Inc, H1 2017
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Pipeline by Novartis AG, H1 2017
Pipeline by Onconova Therapeutics Inc, H1 2017
Pipeline by Pfizer Inc, H1 2017
Pipeline by Teijin Pharma Ltd, H1 2017
Pipeline by Tiziana Life Sciences Plc, H1 2017
Pipeline by ViroStatics srl, H1 2017
Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *